Search

Serena M Mershon

from Wakefield, MI
Age ~49

Serena Mershon Phones & Addresses

  • Wakefield, MI
  • Hawk Point, MO
  • Bessemer, MI
  • Saint Louis, MO
  • Saint Charles, MO
  • Columbus, OH

Publications

Us Patents

Pyrazole Compounds As Protein Kinase Inhibitors

View page
US Patent:
20080113971, May 15, 2008
Filed:
Dec 17, 2007
Appl. No.:
11/958229
Inventors:
Cathleen Hanau - Chesterfield MO, US
Serena Mershon - Bessemer MI, US
Matthew Graneto - Chesterfield MO, US
Marvin Meyers - St. Charles MO, US
Ingrid Buchler - South University City MO, US
Shridhar Hegde - Ballwin MO, US
Kun Wu - Chesterfield MO, US
Shuang Liu - Schenectady NY, US
International Classification:
A61K 31/551
A61K 31/498
C07D 487/04
US Classification:
514221000, 514249000, 540500000, 544350000
Abstract:
Compounds are described which inhibit mitogen activated protein kinase-activated protein kinase-2 (MK-2). Methods of making such compounds are described, as well as a method of using them for the inhibition of MK-2, and for the prevention or treatment of a disease or disorder that is mediated by TNFα, where the method involves administering to the subject an MK-2 inhibiting compound of the present invention. Pharmaceutical compositions and kits which contain the present MK-2 inhibiting compounds are also described.

Acyclic Pyrazole Compounds For The Inhibition Of Mitogen Activated Protein Kinase-Activated Protein Kinase-2

View page
US Patent:
20040152739, Aug 5, 2004
Filed:
Dec 19, 2003
Appl. No.:
10/742494
Inventors:
Cathleen Hanau - Chesterfield MO, US
Serena Mershon - Bessemer MI, US
Matthew Graneto - Chesterfield MO, US
Marvin Meyers - St. Charles MO, US
Shridhar Hegde - Ballwin MO, US
Ingrid Buchler - South University City MO, US
Kun Wu - Chesterfield MO, US
Shuang Liu - Schenectady NY, US
Kassoum Nacro - Guiderland NY, US
Assignee:
Pharmacia Corporation - St. Louis MO
International Classification:
A61K031/4439
A61K031/415
US Classification:
514/341000, 514/406000, 546/275400, 548/377100
Abstract:
Compounds are described which inhibit mitogen activated protein kinase-activated protein kinase-2 (MK-2). Methods of making such compounds are described, as well as a method of using them for the inhibition of MK-2, and for the prevention or treatment of a disease or disorder that is mediated by TNF, where the method involves administering to the subject an MK-2 inhibiting compound of the present invention. Pharmaceutical compositions and kits which contain the present MK-2 inhibiting compounds are also described.
Serena M Mershon from Wakefield, MI, age ~49 Get Report